Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation

Study acronym: END-AF-1
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Nov 2026 → May 2027
See other at-risk trials from Acesion Pharma

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Nov 2026 to May 2027 Show 5 more changesShow less
    • Study completion pushed from Dec 2026 to Jun 2027
    • Study sites: 44 to 46
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 2 of 3 entries
    • Study description expanded, about 3 words
  2. Study sites: 38 to 44
    • Secondary endpoints revised (3)
    • Study title shortened, about 1 word
    v2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Acesion Pharma
2 trials monitored
See 1 trial at risk
Heart Disease
8,814 trials monitored
See 428 trials at risk
Atrial Fibrillation
1,188 trials monitored
See 57 trials at risk
A clinical Randomized Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.
Trial Details
NCT Number NCT07267949
Lead Sponsor Acesion Pharma
Conditions
(from sponsor)		 Atrial Fibrillation (AF)
Related terms Atrial Fibrillation
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov